TABLE OF CONTENTS
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Branded Generics Market – By Therapeutic Application
1.3.2 MEA Branded Generics Market – By Distribution Channel
1.3.3 MEA Branded Generics Market – By Drug Class
1.3.4 MEA Branded Generics Market – By Formulation Type
1.3.5 MEA Branded Generics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Branded Generics Market – Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Experts Opinion
5. MEA Branded Generics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Branded Generics Getting Popular
5.1.2 Increasing Government Initiatives for Promoting Branded Generics
5.2 Market Restraints
5.2.1 Switching Brands, Poorer Clinical Outcomes and Adverse Effects of Generic Medications
5.3 Market Opportunities
5.3.1 Product Differentiation
5.4 Future Trends
5.4.1 Encouraging Utility of Branded Generics by Healthcare Providers and Professionals
5.5 Impact Analysis
6. Branded Generics Market– MEA Analysis
6.1 MEA Branded Generics Market Revenue Forecast and Analysis
6.2 MEA Branded Generics Market, By Country - Forecast and Analysis
7. MEA Branded Generics Market Revenue and Forecast To 2028– by Therapeutic Application
7.1 Overview
7.2 MEA Branded Generics Market Revenue Share, By Therapeutic Application: Market Revenue and Forecast Analysis (US$ Billion)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology Market Revenue and Forecast to 2028 (US$ Billion)
7.4 Cardiovascular Diseases
7.4.1 Overview
7.4.2 Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.5 Diabetes
7.5.1 Overview
7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
7.6 Neurology
7.6.1 Overview
7.6.2 Neurology Market Revenue and Forecast to 2028 (US$ Billion)
7.7 Gastrointestinal Diseases
7.7.1 Overview
7.7.2 Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.8 Dermatology Diseases
7.8.1 Overview
7.8.2 Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.9 Analgesics and Anti-Inflammatory
7.9.1 Overview
7.9.2 Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
7.10 Others
7.10.1 Overview
7.10.2 Others Market Revenue and Forecast to 2028 (US$ Billion)
8. MEA Branded Generics Market Analysis and Forecast to 2028 by Distribution Channel
8.1 MEA Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
8.2 Hospital Pharmacies
8.2.1 Overview
8.2.2 Hospital Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.3 Retail Pharmacies
8.3.1 Overview
8.3.2 Retail Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.4 Online Pharmacies
8.4.1 Overview
8.4.2 Online Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.5 Drug Stores
8.5.1 Overview
8.5.2 Drug Stores: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9. MEA Branded Generics Market Analysis and Forecast to 2028 by Drug Class
9.1 MEA Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
9.2 Alkylating Agents
9.2.1 Overview
9.2.2 Alkylating Agents: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.3 Antimetabolites
9.3.1 Overview
9.3.2 Antimetabolites: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.4 Hormones
9.4.1 Overview
9.4.2 Hormones: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.5 Anti-hypertensive
9.5.1 Overview
9.5.2 Anti-hypertensive: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.6 Lipid Lowering Drugs
9.6.1 Overview
9.6.2 Lipid Lowering Drugs: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.7 Anti-Depressants
9.7.1 Overview
9.7.2 Anti-Depressants: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.8 Anti-psychotics
9.8.1 Overview
9.8.2 Anti-psychotics: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.9 Anti-epileptic
9.9.1 Overview
9.9.2 Anti-epileptic: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.10 Others
9.10.1 Overview
9.10.2 Others: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
10. MEA Branded Generics Market Analysis and Forecast to 2028 – by Formulation Type
10.1 Overview
10.2 MEA Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Billion)
10.4 Parenteral
10.4.1 Overview
10.4.2 Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
10.5 Topical
10.5.1 Overview
10.5.2 Topical Market Revenue and Forecast to 2028 (US$ Billion)
10.6 Others
10.6.1 Overview
10.6.2 Others Market Revenue and Forecast to 2028 (US$ Billion)
11. MEA Branded Generics Market Revenue and Forecasts to 2028 Country Analysis
11.1 Overview
11.1.1 MEA: Branded Generics Market, by Country, 2022 & 2028 (%)
11.1.1.1 UAE: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.1.1.1.1 Overview
11.1.1.1.2 UAE: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.1.3 UAE: Branded Generics Market, by Therapeutic Application, 2019–2028 (US$ Billion)
11.1.1.1.4 UAE: Branded Generics Market, by Distribution Channel, 2019–2028 (US$ Billion)
11.1.1.1.5 UAE: Branded Generics Market, by Drug Class, 2019–2028 (US$ Billion)
11.1.1.1.6 UAE: Branded Generics Market, by Formulation Type, 2019–2028 (US$ Billion)
11.1.1.2 Saudi Arabia: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2.1 Overview
11.1.1.2.2 Saudi Arabia: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2.3 Saudi Arabia: Branded Generics Market, by Therapeutic Application, 2019–2028 (US$ Billion)
11.1.1.2.4 Saudi Arabia: Branded Generics Market, by Distribution Channel, 2019–2028 (US$ Billion)
11.1.1.2.5 Saudi Arabia: Branded Generics Market, by Drug Class, 2019–2028 (US$ Billion)
11.1.1.2.6 Saudi Arabia: Branded Generics Market, by Formulation Type, 2019–2028 (US$ Billion)
11.1.1.3 South Africa: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3.1 Overview
11.1.1.3.2 South Africa: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3.3 South Africa: Branded Generics Market, by Therapeutic Application, 2019–2028 (US$ Billion)
11.1.1.3.4 South Africa: Branded Generics Market, by Distribution Channel, 2019–2028 (US$ Billion)
11.1.1.3.5 South Africa: Branded Generics Market, by Drug Class, 2019–2028 (US$ Billion)
11.1.1.3.6 South Africa: Branded Generics Market, by Formulation Type, 2019–2028 (US$ Billion)
11.1.1.4 Rest of MEA: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4.1 Overview
11.1.1.4.2 Rest of MEA: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4.3 Rest of MEA: Branded Generics Market, by Therapeutic Application, 2019–2028 (US$ Billion)
11.1.1.4.4 Rest of MEA: Branded Generics Market, by Distribution Channel, 2019–2028 (US$ Billion)
11.1.1.4.5 Rest of MEA: Branded Generics Market, by Drug Class, 2019–2028 (US$ Billion)
11.1.1.4.6 Rest of MEA: Branded Generics Market, by Formulation Type, 2019–2028 (US$ Billion)
12. Branded Generics Market–Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 MYLAN N.V.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bausch Health Companies Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Lupin
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Sanofi
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 ASTRAZENECA PLC.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Par Pharmaceuticals, INC
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Sandoz International GMBH
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Aspen Holdings
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Hetero
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms